Workshop Proceedings: Streamlined Development of Safety Assessment Programs Supporting Orphan/Rare Diseases-Are We...

Area of Science:

• Toxicology
• Pharmacology
• Drug Development

Background:

• Rare disease drug development presents unique challenges in nonclinical safety assessment.
• Existing regulatory guidance may require adaptation for orphan/rare disease therapeutics.

Purpose of the Study:

• To discuss nonclinical considerations for developing rare disease therapeutics.
• To identify challenges and progress in preclinical safety assessment for orphan diseases.

Main Methods:

• A workshop format featuring a panel of industry and government experts.
• Review of current guidance and presentation of progress in rare disease drug development.
• Case examples of nonclinical development programs, including enzyme replacement therapy (ERT).

Main Results:

• Nonclinical testing for rare disease therapeutics necessitates specific considerations beyond standard protocols.
• Early engagement with health authorities can streamline the scope and timeline of safety studies.
• Concepts discussed are broadly applicable, though ERTs were a focus.

Conclusions:

• Tailored nonclinical safety programs are essential for rare disease drug development.
• Optimizing development pathways requires proactive sponsor-regulator collaboration.
• Advancements in rare disease therapeutic development are ongoing, with lessons learned from specific examples like ERTs.